Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
16/26/16	CA$0.1150	0.00%	1,67,047
15/26/15	CA$0.1150	0.00%	15,780
14/26/14	CA$0.1150	+4.55%	1,30,240
13/26/13	CA$0.1100	-4.35%	33,831
09/26/09	CA$0.1150	0.00%	16,365

End-of-day quote Toronto S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.1150CAD

Average target price

1.000CAD

Spread / Average Target

+769.57%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Sernova Biotherapeutics Inc

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Sernova Biotherapeutics Inc

Company calendar

End-of-day quote Toronto S.E. 16/10/2026			5-day change	1st Jan Change
0.1150 ^CAD	0.00%		0.00%	-11.54%

11/09	Sernova Biotherapeutics Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2026	CI
09/09	Seraxis Holdings, Inc. entered into a definitive agreement to acquire Sernova Biotherapeutics Inc in a merger of equals, reverse merger transaction.	CI

Market Cap	4.34Cr 3.07Cr 2.73Cr 2.53Cr 2.3Cr 291.39Cr 4.41Cr 30Cr 12Cr 152.06Cr 12Cr 11Cr 484.74Cr	P/E 2026 *	-4.6x	P/E 2027 *	-3.83x
Enterprise Value	4.34Cr 3.07Cr 2.73Cr 2.53Cr 2.3Cr 291.39Cr 4.41Cr 30Cr 12Cr 152.06Cr 12Cr 11Cr 484.74Cr	EV / Sales 2026 *	-	EV / Sales 2027 *	17.4x
Free-Float	89.49%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Toronto S.E.	SVA	End-of-day quote
Toronto S.E.	SVA	Delayed
OTC Markets	SEOVF	Delayed
Boerse Muenchen	PSH0	Real-time
Deutsche Boerse AG	PSH0	Delayed
Börse Stuttgart	PSH0	Delayed
Tradegate	PSH0	Real-time
Xetra	PSH0	Delayed

11/09	Sernova Biotherapeutics Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2026	CI
09/09	Seraxis Holdings, Inc. entered into a definitive agreement to acquire Sernova Biotherapeutics Inc in a merger of equals, reverse merger transaction.	CI
17/06	Sernova's Autologous Islet Transplantation Gets Orphan Drug Designation For Type 3c Diabetes Prevention	MT
12/06	Sernova Biotherapeutics Inc Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026	CI
23/04	Sernova Biotherapeutics Inc announced that it has received CAD 7.564399 million in funding	CI
14/03	Sernova Biotherapeutics Inc Reports Earnings Results for the First Quarter Ended January 31, 2026	CI
05/03	Sernova Biotherapeutics Inc announced that it expects to receive CAD 7.1 million in funding	CI
20/12	Sernova Biotherapeutics Inc Reports Earnings Results for the Full Year Ended October 31, 2025	CI
19/12	Sernova Biotherapeutics Inc Auditor Raises 'Going Concern' Doubt	CI
13/11	Sernova Biotherapeutics Inc announced that it expects to receive CAD 5 million in funding	CI
23/25/23	Sernova Biotherapeutics Inc Appoints John L. Brooks III as Chair of the Board of Directors	CI
16/25/16	Sernova Biotherapeutics Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2025	CI
09/25/09	Sernova Partners With Eledon Pharmaceuticals to Advance Potential Functional Cure for Type 1 Diabetes	MT

Sernova Biotherapeutics Inc Share Price

Stocks

SVA

CA81752F1062

Medical Equipment, Supplies & Distribution

Valuation: Sernova Biotherapeutics Inc

Chart: Sernova Biotherapeutics Inc

Latest news: Sernova Biotherapeutics Inc

Press Releases: Sernova Biotherapeutics Inc

News in other languages: Sernova Biotherapeutics Inc

Quotes and Performance

Price Extremes

Managers and Directors: Sernova Biotherapeutics Inc

Latest insider transactions

Medical Devices & Implants

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

05/10	Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial	AQ
25/09	Sernova Biotherapeutics to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference	AQ
12/09	Steven Sangha Announces Voting and Support Agreement for Sernova Biotherapeutics Inc.'s Proposed Business Combination with Seraxis Holdings, Inc.	NE
10/09	Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference	AQ
08/09	Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated Type 1 Diabetes Islet Cell-Replacement Biotech Company, BetaNova Biotherapeutics	AQ

15/23/15	Sernova-Telefonkonferenz für Investoren, die ursprünglich für den 15. September geplant war, wird nun auf den 22. September verschoben
13/23/13	Sernova veranstaltet Telefonkonferenzen für Investoren zur Vorstellung der neu ernannten CEO und zur Bekanntgabe eines Updates zur Geschäftsentwicklung
03/23/03	AstraZeneca : accord de recherche avec le canadien Sernova
03/23/03	Sernova kündigt Forschungskooperation mit dem Pharmakonzern AstraZeneca an, um neuartige potenzielle Zelltherapie-Anwendungen zu untersuchen
10/23/10	Sernova präsentiert beim 2023 Cell & Gene Meeting on the Med der Alliance for Regenerative Medicine

Current month	+9.52%
1 month	+9.52%
6 months	-37.84%
Current year	-11.54%

1 week	0.1	0.12
1 month	0.08	0.12
Current year	0.08	0.2
1 year	0.08	0.2
3 years	0.08	0.82
5 years	0.08	2.22
10 years	0.08	2.87

Manager	Title	Age	Since
Jonathan Rigby CEO	Chief Executive Officer	59	12/08/2024
Marie Kaldchibachi DFI	Director of Finance/CFO	-	01/11/2023
James Parsons DFI	Director of Finance/CFO	61	07/10/2024

Director	Title	Age	Since
Steven Sangha BRD	Director/Board Member	-	24/04/2023
Jonathan Rigby CHM	Chairman	59	02/06/2025
David Paterson BRD	Director/Board Member	-	01/09/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
03/07/26	SERNOVA BIOTHERAPEUTICS, INC.	Sell	Company	-1,15,000	0.0305%
22/05/26	John Brooks	Option	Chairman	2,28,912	0.0658%
22/05/26	Steven Sangha	Option	Director	2,60,000	0.0748%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SERNOVA BIOTHERAPEUTICS INC	0.00%	0.00%	-34.29%	-84.03%	3.07Cr
ABBOTT LABORATORIES	+0.20%	+5.31%	-18.40%	+13.84%	18TCr
MEDTRONIC PLC	-0.73%	+7.09%	-1.08%	+30.13%	12TCr
STRYKER CORPORATION	+0.49%	+6.25%	-21.30%	+9.62%	11TCr
ESSILORLUXOTTICA	+3.83%	+5.50%	-50.59%	-6.11%	7.98TCr
CENCORA, INC.	-0.14%	+5.27%	+5.00%	+81.87%	6.51TCr
HOYA CORPORATION	+2.79%	+2.37%	+15.85%	+65.97%	5.43TCr
BECTON, DICKINSON AND COMPANY	-1.04%	+4.35%	+1.40%	-26.05%	5.22TCr
IDEXX LABORATORIES, INC.	+2.41%	+8.18%	-11.81%	+28.50%	4.41TCr
DEXCOM, INC.	-1.90%	+2.29%	+29.19%	+6.90%	3.25TCr
Average	+0.59%	+4.76%	-8.60%	+12.06%	7.39TCr
Weighted average by Cap.	+0.60%	+5.59%	-11.14%	+21.17%

	2026 *	2027 *
Net sales	-	25L 17.67L 15.71L 14.56L 13.25L 17Cr 25.4L 1.75Cr 68.63L 8.75Cr 66.33L 64.92L 28Cr
Net income	-1.13Cr -79.89L -71.01L -65.82L -59.88L -76Cr -1.15Cr -7.91Cr -3.1Cr -40Cr -3Cr -2.93Cr -126.13Cr	-1.39Cr -98.27L -87.35L -80.96L -73.66L -93Cr -1.41Cr -9.73Cr -3.82Cr -49Cr -3.69Cr -3.61Cr -155.15Cr
Net Debt	-	-